Clinical Trial Detail

NCT ID NCT03827473
Title Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Prednisone

Docetaxel

Age Groups: adult senior

No variant requirements are available.